doripenem (doribax) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Doripenem is a synthetic carbapenem that has broad antibacterial potency against aerobic and anaerobic gram-positive and gram-negative bacteria. Doripenem is structurally related to beta-lactam antibiotics and shares the bactericidal mode of action of other β-lactam antibiotics by targeting penicillin-binding proteins (PBPs) to inhibit the biosynthesis of the bacterial cell wall. Doripenem is resistant to hydrolysis by most β-lactamases and is resistant to inactivation by renal dehydropeptidases. Doripenem has many similarities to the other carbapenems, as well as some important differences, such as greater potency against Pseudomonas aeruginosa. It was found to be similar to comparator agents. The most common adverse effects related to doripenem therapy were headache, nausea, diarrhea, rash, and phlebitis.   NCATS

Chemistry

  • SMILES: C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N2C1=O)C(O)=O
  • InChIKey: AVAACINZEOAHHE-VFZPANTDSA-N
  • Mol. Mass: 420.504
  • ALogP: -1.6
  • ChEMBL Molecule:
    doripenem  
More Chemistry

Pharmacology

Alternative names

2-(5-sulfamoylaminomethylpyrrolidin-3-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapen-2-em-3-carboxylic acid | doribax | doripenem | doripenem hydrate | finibax | s 4661 | s-4661

Organizations (16)

Research & Development (15)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (28)

Approved Indications (4)


 

Cholecystitis

Intraabdominal Infections

Pyelonephritis

Urinary Tract Infections

Experimental Indications - Clinical Trial Phases 1-4 (28)


 

Abdomen, Acute (Phase 3)

Abdominal Abscess (Phase 3)

Abdominal Pain (Phase 3)

Appendicitis (Phase 3)

Bacteremia (Phase 2/Phase 3)

Bacterial Infections (Phase 4)

Bacterial Infections and Mycoses (Phase 3)

Cholecystitis (Phase 3)

Community-Acquired Infections (Phase 3)

Cross Infection (Phase 4)

Febrile Neutropenia (Phase 4)

Healthcare-Associated Pneumonia (Phase 2/Phase 3)

Healthy Volunteers (Phase 4)

Ileus (Phase 3)

Infections (Phase 4)

Intestinal Perforation (Phase 3)

Intraabdominal Infections (Phase 4)

Meningitis (Phase 1)

Pancreatitis (Phase 3)

Peritonitis (Phase 3)

Pneumonia (Phase 4)

Pneumonia, Bacterial (Phase 3)

Pneumonia, Ventilator-Associated (Phase 4)

Pyelonephritis (Phase 3)

Rupture (Phase 3)

Sepsis (Phase 4)

Urinary Tract Infections ()

Ventilators, Mechanical (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 26
  • # of Trial Organizations: 15

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue